Nature communications · 2025
Identification of epigenetic regulators of fibrotic transformation in cardiac fibroblasts through bulk and single-cell CRISPR screens.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aguado-Alvaro Laura Pilar, Garitano Nerea, Esser-Skala Wolfgang, Sayers Judy, Del Valle Cynthia, Alameda Daniel, Mendieta-Esteban Julen, Calleja-Cervantes Maria Erendira, Goñi-Salaverri Ainhoa, Zazpe Jon, de Vito Anna Rosaria, Marchese Francesco, Alignani Diego, Cudini Juliana, Gross Torsten, Rábago Gregorio, Narayan Nisha, Martinez Laura, Martinez Sonia, Huntly Brian, Riley Paul, Gonzalez Arantxa, Taylor-King Jake P, Fortelny Nikolaus, Pelacho Beatriz, Lara-Astiaso David
Аннотация
Cardiac fibrosis is mediated by the persistent activity of myofibroblasts, which differentiates from resident cardiac fibroblasts in response to tissue damage and stress signals. The signaling pathways and transcription factors regulating fibrotic transformation have been thoroughly studied. In contrast, the roles of chromastin factors in myofibroblast differentiation and their contribution to pathogenic cardiac fibrosis remain poorly understood. Here, we combined bulk and single-cell CRISPR screens to characterize the roles of chromatin factors in the fibrotic transformation of primary cardiac fibroblasts. We uncover strong regulators of fibrotic states including Srcap and Kat5 chromatin remodelers. We confirm that these factors are required for functional processes underlying fibrosis including collagen synthesis and cell contractility. Using chromatin profiling in perturbed cardiac fibroblasts, we demonstrate that pro-fibrotic chromatin complexes facilitate the activity of well-characterized pro-fibrotic transcription factors. Finally, we show that KAT5 inhibition alleviates fibrotic responses in patient-derived human fibroblasts.